Search

Your search keyword '"H. Bea Kuiperij"' showing total 98 results

Search Constraints

Start Over You searched for: Author "H. Bea Kuiperij" Remove constraint Author: "H. Bea Kuiperij"
98 results on '"H. Bea Kuiperij"'

Search Results

1. No replicating evidence for anti‐amyloid‐β autoantibodies in cerebral amyloid angiopathy‐related inflammation

2. Altered brain expression and cerebrospinal fluid levels of TIMP4 in cerebral amyloid angiopathy

3. Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy

4. The relation of a cerebrospinal fluid profile associated with Alzheimer’s disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy

5. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy

6. Cerebrospinal fluid shotgun proteomics identifies distinct proteomic patterns in cerebral amyloid angiopathy rodent models and human patients

7. Correction: Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid angiopathy

8. Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy

9. Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy

10. Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach

11. MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy

12. Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy

13. Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage

14. Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms

15. Correction to: Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy

16. Multicenter Analytical Validation of Aβ40 Immunoassays

17. Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy

18. Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer's Disease

19. Urokinase plasminogen activator (uPA) as a novel biomarker for cerebral amyloid angiopathy

22. Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach

23. MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy

24. Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls

25. Neuroleukin: A potential cerebrospinal fluid biomarker for Alzheimer's disease

26. Platelet‐derived growth factor receptor‐beta as a potential CSF biomarker for Alzheimer’s disease

27. Urokinase plasminogen activator (uPA) as a novel biomarker for cerebral amyloid angiopathy

28. Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson’s disease

29. Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage

30. Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy

31. Proteomic profiling of striatal tissue of a rat model of Parkinson's disease after implantation of collagen-encapsulated human umbilical cord mesenchymal stem cells

33. Additional file 6 of Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage

34. Additional file 3 of Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage

36. Additional file 2 of Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage

37. CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD

38. Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms

39. Serum NFL discriminates Parkinson disease from atypical parkinsonisms

40. MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy

41. Limitations of the hCMEC/D3 cell line as a model for Aβ clearance by the human blood-brain barrier

42. Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study

43. CSF d-serine concentrations are similar in Alzheimer's disease, other dementias, and elderly controls

44. Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders

45. Plasma Abeta (Amyloid-beta) Levels and Severity and Progression of Small Vessel Disease

46. MicroRNA-29a Is a Candidate Biomarker for Alzheimer’s Disease in Cell-Free Cerebrospinal Fluid

47. Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders

48. [P4–394]: ASSOCIATIONS OF PLASMA AMYLOID BETA LEVELS WITH SEVERITY AND PROGRESSION OF CEREBRAL SMALL VESSEL DISEASE

49. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes

50. Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson’s disease and controls

Catalog

Books, media, physical & digital resources